Ensuring Study Integrity and Reliability During a Drug Recall: Technology and Services Delivered on Schedule
When clinical development teams hear the words “safety/drug recall,” tension immediately arises. Ensuring the safety of the patient and preventing the potential for unblinding is of the utmost importance. This case study uncovers the steps a Sponsor and their Interactive Response Technology partner took to ensure the study continued without unblinding, loss of patients, or delay.
You will learn:
- Ways to ensure patients are not dispensed the effected product
- Innovative strategies for dosing options to ensure unblinding doesn’t occur
- How to avoid delays due to insufficient supplies and preserve continuity of the study